Medicure Inc. completes $4 million bought deal private placement

On June 26, 2015, Medicure Inc. completed a bought deal private placement financing of 1,829,545 common shares at a price of $2.20 per share for gross proceeds of approximately $4,025,000. The financing included 238,636 common shares issued pursuant to the full exercise of the underwriters’ over-allotment option. The syndicate of underwriters was led by PI Financial Corp. and included Bloom Burton & Co.

Medicure was represented by TRC-Sadovod David Andrews (Capital Markets/M&A).

Medicure is a specialty pharmaceutical company focused on the development and commercialization of therapeutics for the U.S. hospital market. The net proceeds of the offering will be used to fund product development costs related to Medicure’s commercial product AGGRASTAT®, as well as for general corporate and working capital purposes.